1. Scrip
  2. >>Business

Roche Secures Dicerna RNAi Deal For Hepatitis B

Roche Pays $200m Up Front For DCR-HBVS Candidate

 
• By Alexandra Shimmings

Roche has paid $200m up front to get its hands on Dicerna’s RNAi-based drug for chronic hepatitis B in a deal that could be worth around $1.5bn.

Hepatitis B
Hepatitis B Virus • Source: Shutterstock

Roche is taking aim at curing chronic hepatitis B, signing a deal with RNAi specialist Dicerna Pharmaceuticals Inc. for use of its GalXC platform technology, focusing on the drug candidate DCR-HBVS, for an upfront payment of $200m.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

 
• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.

Could There Be A Cure For Cardiometabolic Disease? Novo Nordisk Foundation Wants To Help Academics Find Out

 
• By Andrew McConaghie

The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.